Related Experiment Videos
[Immunomodulator Cycloferon in the comprehensive treatment of patients with acute non-lymphoblastic leukemia]
S I Moiseev1, K M Abdulkadyrov, L N Bubnova
1Russian Research Institute of Hematology and Transfusiology, St. Petersburg.
Voprosy Onkologii
|October 26, 1999
Abstract:
The therapeutic benefit and action of the immunomodulator Cycloferon were evaluated in patients with acute non-lymphoblastic leukemia. When administered in conjunction with chemotherapy during first complete remission, it reduced both early-onset relapse frequency and degree of cytostatic-induced immune deficiency. The drug's action is mediated by changes taking place in cytokine and interferon synthesis.